Prelude Therapeutics reports FY2023 net loss of $121.8M; cash runway into 2026, pipeline milestones set for 2024

Prelude Therapeutics Inc

2023-FY EPS reported -$2.02

Cash and marketable securities $232.9M as of Dec 31, 2023, expected to fund operations into 2026.
Net loss $121.8M ($2.02/share) for FY2023 vs $115.4M ($2.44/share) for FY2022.
R&D expenses increased to $103.4M from $92.9M; G&A expenses decreased to $28.9M from $30.7M.
PRT3789 (SMARCA2 degrader) on track for monotherapy dose escalation mid-2024; combo with docetaxel initiated H1 2024.
PRT2527 (CDK9 inhibitor) to initiate combo with zanubrutinib Q1 2024; PRT7732 (oral SMARCA2 degrader) IND filing H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Prelude Therapeutics Inc reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-015913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.